[Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance]. / Antagonistes de l'angiotensine II et cancer: un bilan rassurant.
Rev Med Suisse
; 7(308): 1757-8, 1760, 2011 Sep 14.
Article
em Fr
| MEDLINE
| ID: mdl-21954817
ABSTRACT
The effects of drugs on new cancer and cancer-related death are a major concern. Recently, a meta-analysis raised the possibility that ARBs might have an adverse impact in this respect. This point of view was highly debated until the publication of two other meta-analyses which did not demonstrate any increased risk of new cancer occurrence as well as of cancer related-death with the use of ARBs in patients with hypertension, heart failure and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically in order to avoid biased conclusions. Overall the bulk of evidence today indicates that ARBs are not associated with an increased cancer risk.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antagonistas de Receptores de Angiotensina
/
Hipertensão
/
Neoplasias
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
Fr
Ano de publicação:
2011
Tipo de documento:
Article